Western Digital Corporation Unveiled New Advancements at Computex 2025
During the event, Western Digital Corporation (NASDAQ:WDC) announced the expansion of the Open Composable Compatibility Lab, which is being upgraded to version 2.0. Moreover, the company also introduced OpenFlex Data24 4100 EBOF, which is a new addition to the Data24 series and uses single-port SSDs.
A data center filled with racks of hard disk drives and solid state drives.
Western Digital Corporation (NASDAQ:WDC) also introduced Ultrastar Data102 3000 ORv3 JBOD at Computex 2025. The product not only meets the latest Open Rack v3 specifications but is designed for cloud data centers. Management noted that these updated products are critical in helping organizations with their growing data demands.
Western Digital Corporation (NASDAQ:WDC) is a tech company that develops data storage solutions and devices.
While we acknowledge the potential of WDC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Erreur lors de la récupération des données
Connectez-vous pour accéder à votre portefeuille
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
20 minutes ago
- Associated Press
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Luminar Technologies, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - August 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Luminar Technologies, Inc. (NASDAQ: LAZR) between March 20, 2025 and May 14, 2025, both dates inclusive (the 'Class Period'), of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Luminar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Luminar class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Austin Russell ('Russell'), Luminar's President, CEO and Chairman of the Board, was engaged in undisclosed conduct that would make him the subject of an inquiry by the Audit Committee of the Board of Directors; (2) this conduct created material risk that Russell would be released form his positions at Luminar; (3) Luminar's loss of Russell as an employee would then create material risk of adversely affecting Luminar's business by making it more difficult to compete with other market participants, manage R&D activities, and retain existing customers or cultivate new ones. Further, negative public perception and negative news related to Russell could adversely affect Luminar's brand relationships with customers, or standing in the industry; (4) accordingly, Luminar had no reasonable basis to provide and/or maintain Luminar's financial guidance; and (5) as a result, defendants' public statements were materially false and/or misleading at all times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Luminar class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
Associated Press
20 minutes ago
- Associated Press
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--Aug 18, 2025-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company') plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to the timing of the Company's financial reporting and the Company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. View source version on CONTACT: PureTech Public Relations [email protected] Investor Relations [email protected] KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH FDA CLINICAL TRIALS SOURCE: PureTech Health plc Copyright Business Wire 2025. PUB: 08/18/2025 02:00 AM/DISC: 08/18/2025 01:59 AM
Yahoo
an hour ago
- Yahoo
What Canadian National Railway (TSX:CNR)'s Reduced Earnings Guidance Means For Shareholders
Earlier this month, Canadian National Railway faced ongoing operational challenges and reported that its expected business turnaround had not materialized, leading to reduced earnings growth guidance. This setback has sparked negative sentiment, with some industry observers drawing comparisons to competitors viewed as better positioned for growth and highlighting alternatives within the sector. With reduced earnings growth guidance in focus, we'll explore how these operational issues may shift Canadian National Railway's investment narrative. AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Canadian National Railway Investment Narrative Recap To be a shareholder in Canadian National Railway, you need confidence in the company's ability to capitalize on long-term shifts toward intermodal and bulk transport as industries focus on supply chain resilience and North American trade. However, the recent reduction in earnings growth guidance directly impacts the key short-term catalyst, an expected business turnaround, and highlights concerns around volume growth, currently the most prominent risk for the business. The news meaningfully shifts investor attention from network advantages to near-term operational execution. Among recent announcements, the second-quarter results stand out. While CN grew net income and earnings per share compared to the prior year, sales have edged lower, reflecting the ongoing volume and demand pressures underpinning the news event. This reinforces the theme that even targeted capital spending and cost discipline will take time to translate into renewed growth, particularly if market conditions stay challenging. In contrast, investors should also be aware that structural shifts in customer routing and industry competitiveness could... Read the full narrative on Canadian National Railway (it's free!) Canadian National Railway's narrative projects CA$19.6 billion revenue and CA$5.6 billion earnings by 2028. This requires 4.6% yearly revenue growth and a CA$1.0 billion earnings increase from CA$4.6 billion today. Uncover how Canadian National Railway's forecasts yield a CA$153.14 fair value, a 19% upside to its current price. Exploring Other Perspectives Simply Wall St Community members provided 12 fair value estimates for CNR ranging from CA$119.59 to CA$170.64 per share. These divergent opinions come as growth in shipping volumes remains a critical uncertainty for the company's ability to regain momentum, explore the range of forecasts and viewpoints from across the Community. Explore 12 other fair value estimates on Canadian National Railway - why the stock might be worth 7% less than the current price! Build Your Own Canadian National Railway Narrative Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your Canadian National Railway research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Our free Canadian National Railway research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Canadian National Railway's overall financial health at a glance. Want Some Alternatives? Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay: Outshine the giants: these 19 early-stage AI stocks could fund your retirement. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
